Olanzapine

證據等級: L5

預測適應症: 3 個

Olanzapine: From Antipsychotic Use to Treatment-Resistant Panic Disorder with Agoraphobia

One-Sentence Summary

Olanzapine is an atypical (second-generation) antipsychotic; this evidence pack does not include a specific original-indication text, but olanzapine is widely known for treating schizophrenia and bipolar disorder. TxGNN’s highest-scoring prediction (benign paroxysmal torticollis of infancy) was reviewed and rejected as mechanistically implausible and potentially unsafe (see note below). Of the remaining candidates, Agoraphobia (in the context of treatment-resistant panic disorder) is the most credible, supported by 1 open-label trial and 7 publications, though all evidence remains observational/uncontrolled (L3).

Quick Overview

Item	Content
Original Indication	Not specified in evidence pack (olanzapine is a known atypical antipsychotic; original_indications field was empty)
Predicted New Indication	Agoraphobia (treatment-resistant panic disorder, augmentation therapy)
TxGNN Prediction Score	99.47%
Evidence Level	L3
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, olanzapine is part of the atypical (second-generation) antipsychotic class, with established efficacy in psychotic and mood disorders via combined 5-HT2A, D2, noradrenergic, and histaminergic receptor antagonism. Its FDA-approved combination with fluoxetine (Symbyax) for treatment-resistant depression and bipolar depression demonstrates that this multi-receptor profile can extend beyond core psychotic symptoms into mood and anxiety domains.

Agoraphobia is most often studied clinically as a comorbid feature of panic disorder rather than as an isolated diagnosis. The mechanistic rationale here is that olanzapine’s sedative/anxiolytic properties support its use as an augmentation agent in SSRI-resistant panic disorder — a secondary, adjunctive mechanism rather than a primary anti-anxiety design target. This is a biologically plausible but indirect link, consistent with the L3 evidence tier assigned.

Note on the top-ranked TxGNN candidate: TxGNN’s highest-scoring prediction for olanzapine was benign paroxysmal torticollis of infancy (score 99.54%, rank 11202). This candidate was reviewed and rejected: it is a self-limited, infancy-onset vestibular/vagal condition, and olanzapine (a D2/5-HT2A antagonist) is clinically known to induce extrapyramidal symptoms and acute dystonia — a mechanism that opposes, rather than supports, treatment of torticollis. The high TxGNN score likely reflects a knowledge-graph confound between “antipsychotic-induced movement disorder” and “antipsychotic-treats-movement-disorder” relationships. Antipsychotics are also not indicated in infants. This candidate is not carried forward in this report (decision stage S0, recommendation: Hold).

Clinical Trial Evidence

Currently no related clinical trials registered.

(One open-label trial (PMID 16415705) exists but is indexed as literature rather than a registered clinical trial record — see Literature Evidence below.)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40946318	2025	Review	Psychotherapy and Psychosomatics	Systematic review of pharmacological, psychotherapeutic, and neurostimulatory options for treatment-resistant anxiety disorders
26635099	2016	Review	Expert Opinion on Pharmacotherapy	Systematic review of treatment-resistant panic disorder; ~1/3 of patients have persistent symptoms despite standard therapy
25012437	2014	Cohort	Journal of Affective Disorders	Comorbid agoraphobia/panic/OCD associated with worse 24-month outcomes in bipolar I disorder
16415705	2006	Open-label Trial	Journal of Clinical Psychopharmacology	12-week, fixed-dose (5 mg/d) olanzapine augmentation in 31 SSRI-resistant panic disorder patients with/without agoraphobia; showed efficacy signal
17099612	2006	Case Report	Psychiatria Danubina	CBT-based treatment of panic disorder with agoraphobia comorbid with psychosis
15470803	2004	Case Report	Pharmacopsychiatry	Olanzapine + paroxetine combination associated with full remission in refractory panic disorder
10739446	2000	Case Report	American Journal of Psychiatry	Early case report describing olanzapine’s effect on panic attacks

Safety Considerations

Please refer to the package insert for safety information.

Data gap flagged as Blocking: TFDA-equivalent label warnings/contraindications (DG001) have not yet been retrieved. This evidence pack notes that this gap currently prevents completion of the initial safety screening (S1) for any olanzapine repurposing candidate. Given olanzapine’s known class-level risks (metabolic syndrome, weight gain, dyslipidemia, QT prolongation, extrapyramidal symptoms), a full label review is required before any clinical advancement.

Additional TxGNN-Predicted Indication: Dysthymic Disorder

For completeness, TxGNN’s third candidate (score 99.28%, rank 16083) — Dysthymic Disorder — is also L3/S1 (“Research Question”) and worth noting alongside agoraphobia:

Rationale: Olanzapine’s multi-receptor profile (5-HT2A, D2, NE, H1) is already leveraged in the FDA-approved olanzapine–fluoxetine combination (Symbyax) for treatment-resistant depression and bipolar depression. Extension to dysthymia (chronic low-grade depression) is mechanistically plausible as an augmentation strategy, but current evidence comes largely from comorbid populations (e.g., borderline personality disorder with dysthymia) in open-label studies, not dysthymia-specific controlled trials. The long-term metabolic risk profile warrants caution given the chronic nature of dysthymia treatment.

PMID	Year	Type	Journal	Key Findings
21154393	2010	Review (Cochrane)	Cochrane Database of Systematic Reviews	Systematic review of second-generation antipsychotics as augmentation for MDD and dysthymia
34727399	2021	Review	Human Psychopharmacology	Meta-analysis of amisulpride (related benzamide class) for depressive symptoms across psychiatric disorders
11920152	2002	Review	Molecular Psychiatry	Reviews substituted benzamides’ dual efficacy in dysthymia and schizophrenia negative symptoms, exploring shared mechanism
22938165	2012	Review	Bipolar Disorders	Evidence-based options for treatment-resistant bipolar disorder, including antipsychotic augmentation
10578457	1999	Open-label Trial	Biological Psychiatry	Open-label olanzapine trial in borderline personality disorder with comorbid dysthymia; safety/efficacy signal

Conclusion and Next Steps

Decision: Hold

Rationale: All three TxGNN-predicted indications for olanzapine rely on L3-or-lower evidence (no completed RCTs), and the Blocking data gap on TFDA-equivalent label warnings (DG001) means the safety screening step (S1) cannot be formally completed for any candidate. The top-ranked prediction (torticollis of infancy) has been independently rejected as mechanistically implausible and unsafe.

To proceed, the following is needed:

Retrieve TFDA/FDA label warnings and contraindications (DG001, Blocking) before any further scoring
Confirm detailed mechanism of action (DG002) to strengthen mechanistic-link analysis
For agoraphobia: seek controlled (RCT-level) data on olanzapine augmentation in SSRI-resistant panic disorder/agoraphobia, given only one small open-label trial (n=31) currently exists
For dysthymic disorder: seek dysthymia-specific (rather than comorbid-population) controlled trial data
Formal exclusion documentation for benign paroxysmal torticollis of infancy to prevent recurrence in future TxGNN re-scoring cycles
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.